
Human Umbilical Cord Blood Infusion Improves Fatigue in Long-COVID
Summary: StemCyte announced phase IIa clinical trial results for RegeneCyte (HPC, cord blood) in treating post-COVID syndrome, with 85% of patients experiencing complete relief from fatigue symptoms compared to 20% in the placebo group. The trial, involving 30 participants, met its primary and secondary endpoints, demonstrating both safety and efficacy. The treatment significantly reduced fatigue…